Inventiva SA
PAR:IVA

Watchlist Manager
Inventiva SA Logo
Inventiva SA
PAR:IVA
Watchlist
Price: 3.76 EUR 1.08%
Market Cap: 718.5m EUR

Operating Margin
Inventiva SA

-720.4%
Current
-823%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-720.4%
=
Operating Profit
-98m
/
Revenue
13.6m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
FR
Inventiva SA
PAR:IVA
718.5m EUR
-720%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
396.2B USD
33%
US
Amgen Inc
NASDAQ:AMGN
176.3B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
147.9B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.4B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
28%
AU
CSL Ltd
ASX:CSL
84B AUD
26%
NL
argenx SE
XBRU:ARGX
45.1B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.9B USD
8%
No Stocks Found

Inventiva SA
Glance View

Market Cap
718.5m EUR
Industry
Biotechnology

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

IVA Intrinsic Value
2.01 EUR
Overvaluation 47%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-720.4%
=
Operating Profit
-98m
/
Revenue
13.6m
What is the Operating Margin of Inventiva SA?

Based on Inventiva SA's most recent financial statements, the company has Operating Margin of -720.4%.

Back to Top